This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Updated from 2:21 p.m. EDT

Medical-device makers were among the best health care performers of Friday's session.

Stryker (SYK - Get Report), which fell on Thursday despite beating first-quarter earnings targets, today closed up 1.2% to $67. Boston Scientific (BSX) added 2.3%, and Medtronic (MDT) gained 1.2%.

Avanir Pharmaceuticals (AVNR) continued its recent march higher. Avanir has soared about 265% this week. On Wednesday, the company said it saw positive results from a late-stage clinical trial for diabetic neuropathic pain drug Zenvia. Avanir closed up 50 cents, or 12.8%, to $4.40.

Monogram Biosciences (MGRM) was also riding momentum. Thomas Weisel Partners, which began coverage of the stock recently with a rating of market weight, said Monogram's revenue will continue to climb into 2008. The stock, which is up 23% for the week, closed up 23 cents, or 11.1%, to $2.31.

The Nasdaq Biotechnology Index, of which both Avanir and Monogram are components, was higher by only 0.6%. The Amex Pharmaceutical Index was up 0.5%, despite a number of components losing ground.

Shares of Merck (MRK - Get Report) were 2.7% higher after Prudential upped its stock price target for the drugmaker to $55 from $48.

But rival Schering-Plough (SGP) slid after both AG Edwards and HSBC Securities downgraded the stock. Schering-Plough was down 29 cents, or 0.9%, to $30.71.

Also among losers, Pfizer (PFE - Get Report) said its most-recent quarter was better than expected, but the drugmaker took down its full-year forecast for profits, the low end of which would be more than 10 cents short of what Wall Street wanted to see. Pfizer was off 0.4% to $26.97.

Other pharmaceutical companies were mixed. AstraZeneca (AZN) was up 1.1%, Bristol-Myers Squibb (BMY - Get Report) was up 0.9%, and Eli Lilly (LLY) gained 0.9%.

Elsewhere, Amgen (AMGN) was down 0.6%, Teva Pharmaceutical (TEVA) was down 0.9%, and Wyeth (WYE) was up 0.3%.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AVNR $16.96 0.00%
BMY $72.18 0.00%
MRK $54.84 0.00%
PFE $32.71 0.00%
SYK $109.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs